Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS

In the 12-month phase 3 TRANSFORMS study, fingolimod showed greater efficacy than intramuscular interferon beta (IFNβ)-1a in patients with relapsing–remitting multiple sclerosis (RRMS). This study analyzed fingolimod efficacy compared with IFNβ-1a in patient subgroups from TRANSFORMS. Patients were...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Cohen, Jeffrey A., Barkhof, Frederik, Comi, Giancarlo, Izquierdo, Guillermo, Khatri, Bhupendra, Montalban, Xavier, Pelletier, Jean, Eckert, Benjamin, Häring, Dieter A., Francis, Gordon
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3737385/
https://ncbi.nlm.nih.gov/pubmed/23632946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00415-013-6932-0
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items